According to WHO statistics, nearly 2.3 million of the 19.3 million new cancer cases in the world are breast cancer patients, accounting for 11.7% of the global new cancer cases in 2020. Among them, triple-negative breast cancer (ER-, PR-, HER2-) accounts for 15-25% of all breast cancer cases, which makes the treatment of triple-negative breast cancer very difficult.
EphA10 is a member of the Ephrin receptor family, which is the largest receptor tyrosine kinases (RTKs) family. RTKs play important roles in development, angiogenesis and cell differentiation. It have been pointed out that EphA10-targeted monoclonal antibodies have the potential for cancer immunotherapy and have the following features: (1) In addition to the high expression of EphA10 in the testis, the expression of EphA10 in normal tissues is low favoring female dominant cancer treatment; (2) the expression of EphA10 is higher in a variety of cancerous tissues than in normal tissues, especially in breast cancer including triple-negative breast cancer, which undoubtedly provides a very good treatment for triple-negative breast cancer. (3) Deletion of EphA10 in tumor cells will enhance the anti-tumor ability of cytotoxic T cells. Therefore, SOA201 is a developing tri-specific anticancer antibody targeting EphA10 on the tumor cells with the ability of activating dual immune cells, i.e., NK cells and T cells, for cancer treatment.

The product highlights of SOA201 are outlined as follows:
1. Triple Specific Antibody Targeting of Dual Immune Cells: SOA201 boasts a distinctive feature of employing triple-specific antibodies to effectively target both immune cells.
2. High Expression of EphA10 on Triple-Negative Breast Cancer Cells: Expression of EphA10 on tumor cells especially on triple-negative breast cancer cells, compared with normal cells, SOA201 has a high level of safety range, that makes EPHA10 itself a good target of triple-negative breast cancer for anticancer drug development.
3. T Cells and NK Cells Activator: SOA201 is strategically designed to activation and proliferation of T cells and NK cells, thus augmenting the therapeutic effectiveness of cancer immunotherapy.
4. Broad-Spectrum Anticancer Efficacy: In addition to breast cancer, SOA201 is potentially effective to lung cancer, ovarian cancer, and other solid tumors.